PNPLA3 rs1136201: Understanding Genetic Liver Health Associations
The PNPLA3 rs1136201 variant is a genetic change located within the PNPLA3 gene, which plays a critical role in how the liver processes fats. This variant is widely studied for its association with an increased susceptibility to non-alcoholic fatty liver disease (NAFLD), now often referred to as metabolic dysfunction-associated steatotic liver disease (MASLD).
What each genotype means
Baseline liver risk
This genotype is considered the reference or common form of the PNPLA3 gene. Individuals with this profile do not carry the specific genetic variant associated with increased susceptibility to non-alcoholic fatty liver disease (NAFLD).
This is the most common genotype globally, though its prevalence varies significantly by ancestry.
Increased liver fat risk
Carrying one copy of the G allele (also known as the I148M variant) is associated with a higher risk of accumulating fat in the liver compared to non-carriers. Research suggests that individuals with this genotype may have different responses to dietary interventions, such as carbohydrate restriction, and should discuss liver health and lifestyle management with their healthcare provider.
This heterozygous genotype is found in a significant portion of the global population, with higher frequencies observed in Hispanic populations.
Elevated liver disease risk
Individuals with two copies of the G allele (the I148M variant) have a significantly higher risk of developing hepatic steatosis, steatohepatitis, and related liver complications. Studies indicate that this genotype may reduce the effectiveness of certain treatments like omega-3 fatty acid supplementation for liver fat reduction; please consult your clinician or pharmacist regarding personalized management strategies.
This homozygous genotype is less common than the others but is notably more prevalent in Hispanic populations compared to European or African ancestries.
What is the rs1136201 Variant?
The rs1136201 variant is a single nucleotide polymorphism (SNP) located within the PNPLA3 gene. In genetics, a SNP represents a variation at a single position in the DNA sequence among individuals. This specific variant is situated on chromosome 22. While many genetic variations have no observable effect on health, researchers have identified rs1136201 as a marker of interest because it sits within a gene that is highly active in the liver. By studying where this variant sits in the genome, scientists can better understand how specific DNA sequences influence the production of proteins involved in lipid metabolism. It is important to note that the presence of a variant does not guarantee the development of a condition; rather, it indicates a statistical association observed in large-scale population studies that researchers use to map the genetic architecture of complex traits like liver health.
The Role of the PNPLA3 Gene
The PNPLA3 gene encodes a protein known as patatin-like phospholipase domain-containing protein 3. This protein is primarily found in the liver, where it associates with lipid droplets—the cellular structures that store fat. Research suggests that the PNPLA3 protein acts as a lipase, an enzyme that helps break down triglycerides. When the gene functions normally, it helps maintain a healthy balance of fat storage and mobilization within liver cells, known as hepatocytes. However, variations in this gene can alter the protein's structure or function, potentially leading to the accumulation of lipids in the liver. Because the liver is the central hub for processing dietary fats, any disruption in the proteins that manage these lipids can have downstream effects on liver health, contributing to the development of steatosis, or the buildup of fat in the liver tissue.
Research and Evidence Strength
The association between PNPLA3 variants and liver health is supported by a significant body of research, including genome-wide association studies (GWAS). These studies have consistently identified PNPLA3 as a primary genetic contributor to the spectrum of metabolic dysfunction-associated steatotic liver disease (MASLD). The evidence for these associations is considered moderate to strong in the scientific community, as multiple independent cohorts have replicated the findings. Research indicates that certain alleles of this gene are linked to increased hepatic lipid content and may influence the progression of liver disease, including inflammation and fibrosis. While the statistical link is robust, the biological mechanisms are complex, involving interactions between genetics, diet, and body mass index. Scientists continue to investigate how these genetic factors interact with environmental triggers to drive disease progression, emphasizing that genetics is only one piece of the broader metabolic health puzzle.
What You Can Do With This Information
Understanding your genetic predispositions can be a tool for personal health awareness, but it should never replace professional medical advice. If you are concerned about your liver health or have questions about your genetic results, the most important step is to consult with a healthcare provider, such as a primary care physician or a hepatologist. They can interpret your results in the context of your overall health, including blood tests, lifestyle factors, and medical history. Genetic information is not a diagnosis; it is a statistical probability that can help guide conversations with your doctor about preventative screenings or lifestyle modifications. Avoid making significant changes to your diet or health regimen based solely on a genetic report without first discussing them with a qualified clinician who can provide personalized guidance based on your specific clinical profile.
How common is this variant?
The PNPLA3 variant is common globally, with various alleles appearing in approximately 30% of the population, though frequencies can vary significantly depending on ancestral background.
Frequently asked questions
Does having this variant mean I will get fatty liver disease?
No, having a genetic variant does not mean you will develop a disease. It only indicates a statistical increase in susceptibility, which is influenced by many other factors like diet, exercise, and overall metabolic health.
Can I change my genes if I have this variant?
You cannot change your DNA sequence. However, you can manage your health through lifestyle choices, such as maintaining a balanced diet and regular physical activity, which are known to support liver health regardless of your genetic makeup.
Should I get a liver biopsy if I have this genotype?
Genetic testing results alone are not a reason for invasive procedures like a biopsy. Only a qualified healthcare provider can determine if diagnostic testing is necessary based on your physical symptoms, blood work, and clinical history.
Is this variant the same as the I148M variant?
The I148M variant is a well-known functional change within the PNPLA3 gene often discussed in the context of liver disease. You should consult your specific genetic report or a genetic counselor to understand how your specific rsID relates to the broader scientific literature.
Sources & further reading
Educational information only, last refreshed 10/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1136201?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in PNPLA3
The p.Ile148Met variant in PNPLA3 is a major genetic determinant of hepatic fat content and NAFLD risk.
Intronic regulatory variant in linkage disequilibrium with I148M associated with hepatic fat fraction and ALT levels.
This variant is in high linkage disequilibrium with the I148M (rs738409) variant, which is a major genetic determinant of hepatic fat content and susceptibility to NAFLD.
The PNPLA3 S453I variant is a rare variant associated with hepatic lipid metabolism; note that the common risk variant for NAFLD is rs738409.
An intronic variation in linkage disequilibrium with the major PNPLA3 non-alcoholic fatty liver disease (NAFLD) locus that contributes to individual liver fat accumulation and fibrosis predisposition.
The PNPLA3 I148M variant is a major genetic risk factor for non-alcoholic fatty liver disease (NAFLD) and progression to cirrhosis.